Health News
2005-07-28
Incyte’s
experimental anti-HIV drug shows promise
Reverset, an
experimental nucleoside reverse transcriptase inhibitor
under development by Incyte, shows promise in treati
Reverset, an
experimental nucleoside reverse transcriptase inhibitor
under development by Incyte, shows promise in treating HIV
infection in patients who are resistant to other
antiretroviral medications, researchers reported at
the third International AIDS Society Conference on HIV
Pathogenesis and Treatment in Rio de Janeiro. A six-month
Phase II clinical trial of the medication in nearly
200 HIV-positive adults in the United States and
Europe shows that 200-milligram, once-daily doses of
the medication reduced blood-based viral loads by more than
90% in slightly more than half the study subjects who
had built up resistance to other anti-HIV drugs. The
company plans to launch a final Phase III trial later
this year.
Click here to follow The Advocate on Twitter.
Page 1 of 1